Blockchain Registration Transaction Record

Annovis Bio Launches Long-Term Parkinson's Study for Buntanetap in 2026

Annovis Bio announces a 2026 open-label extension study for buntanetap in Parkinson's disease, evaluating long-term safety and efficacy as a potential disease-modifying therapy.

This news matters because it represents a pivotal step in developing treatments for Parkinson's disease, a progressive neurodegenerative disorder affecting millions worldwide with no cure. Current therapies primarily manage symptoms rather than alter the disease's course. If buntanetap demonstrates long-term safety and efficacy as a disease-modifying therapy, it could potentially slow progression, preserve cognitive and motor function longer, and significantly improve patients' quality of life. For patients and families, this offers hope for more effective long-term management. For the healthcare system, successful disease-modifying treatments could reduce long-term care costs and disability. The extended study also provides valuable real-world data on sustained effects and biomarkers, advancing scientific understanding of neurodegeneration and potentially benefiting research into related conditions like Alzheimer's.